Alnylam pharmaceuticals, inc. (ALNY)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Cash flows from operating activities:
Net loss

-886,116

-761,497

-490,874

-410,108

-290,073

-360,395

-89,225

-106,014

-57,649

-43,515

-47,590

-26,249

Non-cash adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

17,175

15,248

11,898

15,130

19,050

11,926

10,229

9,035

5,125

4,941

5,992

5,726

Amortization and interest accretion related to operating leases

37,193

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-

10,742

-5,163

-5,501

Stock-based compensation

174,841

157,752

92,819

75,528

45,783

33,061

20,703

12,360

16,676

19,118

19,727

18,026

Gain on litigation settlement

0

10,000

0

-

-

-

-

-

-

-

-

-

Charge for 401(k) company stock match

-

-

-

1,507

984

692

449

-364

488

495

-461

382

Fair value adjustments on marketable equity securities

11,288

3,564

-1,894

6,977

-

-

-

-

-

-

-

-

Change in fair value of liability obligation

9,422

0

0

-

-

-

-

-

-

-

-

-

Equity in loss of joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-4,522

-3,505

-7,639

-4,910

-7,646

Tax benefit from stock-based compensation

-

-

-

-

-

-

-

-

-120

-220

-441

-

Other than temporary impairment on equity securities

-

-

-

-

-

-

-

-

595

-

-

-

Realized loss on sale of marketable equity securities

-

-

-

-

-

2,081

-

255

-

-

511

-

Other

-3,191

-5,654

4,379

-

-

-

-

-

-

-

-

-

Impairment on equity investment

-

-

-

-

-

-

-

-

-

-

-

1,561

Gain on issuance of stock by joint venture

-

-

-

-

-

-

-

16,084

-

4,421

-

-

Benefit from intraperiod tax allocation

-

-

-

-

-

-40,209

-2,695

-10,572

-

-

-

-

In-process research and development

-

-

-

-

-

220,766

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

24,238

-15,242

10,668

15,036

-

-

-

-

-

-

-

-

Proceeds from landlord lease incentive for tenant improvements

-30,170

-25,350

0

-2,145

-374

-1,941

-204

-1,780

-

-

-

-581

Inventory

32,411

22,645

0

-

-

-

-

-

-

-

-

-

Billed and unbilled collaboration receivables

-

-

-

-

-31,639

35,689

4,144

-1,364

-1,982

-2,594

1,856

-843

Income taxes receivable

-

-

-

-

-

-

-

-

-10,669

10,669

-

-

Prepaid expenses and other assets

22,042

35,067

20,711

5,276

6,820

5,829

1,356

-1,780

-2,731

2,738

-523

1,748

Accounts payable, accrued expenses and other liabilities

92,354

74,835

26,629

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

10,098

1,676

8,840

1,832

-1,736

-3,512

-3,177

9,901

-1,238

Income taxes payable

-

-

-

-

-

-

-

-

-

-5,516

-467

2,614

Accrued expenses and other liabilities

-

-

-

10,673

6,343

9,122

1,547

-3,591

2,457

651

-341

-3,821

Deferred revenue

392,251

-12,616

1,848

14,615

1,904

-7,786

-6,201

-8,562

-70,255

-60,705

-58,172

66,669

Operating lease liability

33,700

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-278,427

-562,616

-382,786

-307,701

-189,140

-165,641

-68,657

-115,609

-87,068

-84,341

-72,145

65,491

Cash flows from investing activities:
Purchases of property, plant and equipment

140,156

126,887

104,209

64,557

12,950

8,961

4,006

8,348

1,291

4,732

4,949

10,764

Proceeds from maturity of restricted investments

30,000

0

120,000

-

-

-

-

-

-

-

-

-

Purchases of restricted investments and increase in restricted cash

-

-

-

-

1,471

-

-

162

-

-

-6,151

-

Purchases of marketable debt securities

2,075,925

1,104,046

903,457

759,310

1,033,843

977,775

364,305

277,129

293,115

390,473

481,339

482,244

Sales and maturities of marketable securities

1,775,404

1,518,703

597,305

1,116,458

726,943

462,922

237,806

289,013

376,365

413,043

504,570

511,044

Purchases of restricted investments

0

14,825

0

150,000

-

-

-

-

-

-

-

-

Other

7,000

0

0

-

-

-

-

-

-

-

-

-

Payment for asset acquisition

-

-

-

-

-

25,000

-

-

-

-

-

-

Investment in joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-

-

-

10,000

100

Net cash provided by investing activities

-417,677

272,945

-290,361

142,591

-321,321

-548,814

-130,505

3,374

81,959

17,838

14,433

17,936

Cash flows from financing activities:
Proceeds from exercise of stock options and other types of equity, net

71,284

65,470

83,885

14,127

31,137

29,420

28,743

6,971

738

2,670

2,355

4,505

Offering proceeds, net of costs

381,900

0

1,139,625

-

496,400

-

173,572

86,800

-

-

1,154

5,408

Proceeds from issuance of common stock

-

-

-

14,301

89,018

723,037

-

-

-

-

-

-

Proceeds from issuance of long-term debt

-

-

-

150,000

-

-

-

-

-

-

-

-

Repayment of term loan

30,000

0

120,000

-

-

-

-

-

-

-

-

-

Payments for repurchase of common stock for employee tax withholding

-

-

-

596

378

15,992

1,389

359

-

-

-

-

Proceeds from issuance of shares to Novartis

-

-

-

-

-

-

-

-

-

993

-

-

Repayments of notes payable

-

-

-

-

-

-

-

-

-

-

-

6,758

Net cash provided by financing activities

823,184

65,470

1,124,891

177,832

616,177

736,465

200,926

93,412

738

3,663

3,509

3,155

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-83

0

0

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

126,997

-224,201

451,744

12,722

105,716

22,010

1,764

-18,823

-4,371

-62,869

-54,324

86,635

Effect of exchange rate on cash

-

-

-

-

-

-

-

-

-

-29

-121

53

Supplemental disclosure of cash flows:
Cash paid for interest

172

775

2,430

1,096

-

-

-

-

-

-

-

1,499

Cash paid for income taxes

2,566

1,066

114

111

66

-517

-11

-17

10,657

-5,767

-5,836

2,671

Supplemental disclosure of noncash investing and financing activities:
Capital expenditures included in accounts payable and accrued expenses

14,876

33,274

8,176

33,153

1,333

1,526

161

1,441

-

-

-

-

Fair value of common stock issued for asset acquisition

-

-

-

-

-

195,766

-

-

-

-

-

-

Receipt of common stock for exercises of stock options

-

-

-

1,260

686

1,219

-

-

-

-

-

-

Difference in fair value of common stock issued to Sanofi Genzyme less cash proceeds received

-

-

-

-

-

51,450

-

-

-

-

-

-

Repurchase of common stock for employee tax withholding in accrued expenses

-

-

-

-

-

-

600

-

-

-

-

-

Sanofi Genzyme
Proceeds from issuance of common stock

0

0

21,381

-

-

-

-

-

-

-

-

-

Regeneron
Proceeds from issuance of common stock

400,000

0

0

-

-

-

-

-

-

-

-

-